PRODUCT LITERATURE

Roflumilast with long-acting b2-agonists for COPD: influence of exacerbation history

---

The oral, selective phosphodiesterase type-4 inhibitor roflumilast reduces exacerbations and improves lung function in patients with severe-to-very severe chronic obstructive pulmonary disease (COPD). We investigated the efficacy and safety of roflumilast used concomitantly with long-acting b2-
agonists (LABAs) to reduce exacerbations, and the influence of exacerbation history. Pooled data were analysed from two 12-month, placebo-controlled roflumilast (500 mg once daily) studies involving 3,091 patients with severe-to-very severe COPD

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Forespi

Specific Detail Info

Eur Respir J 2011; 38: 553–560

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment